The aim of this meta-analysis was to assess the comprehensive clinical efficacy of dipeptidyl peptidase-IV (DPP-4) inhibitors in Chinese type 2 diabetes patients and to evaluate whether there is a different response to treatment with different kinds of DPP-4 inhibitors in those patients.
Methods:
Databases were systematically searched, and qualifying clinical studies of Chinese type 2 diabetes patients were included.
Results:
A total of 30 studies were included. Treatment with saxagliptin resulted in a significantly greater change from baseline in HbA1c levels (weighted mean difference [WMD], −1.28%; 95% CI, −1.37% to −1.19%); treatment with sitagliptin led to a significantly greater change from baseline (WMD, −1.17%; 95% CI, −1.46% to −0.89%); treatment with vildagliptin was associated with a significantly greater change in HbA1c levels (WMD, −0.77%; 95% CI, −0.88% to −0.65%); treatment with linagliptin led to a significantly greater change (WMD, −0.84%; 95% CI, −0.92% to −0.75%); and treatment with alogliptin also led to a significantly greater change (WMD, −0.91%; 95% CI, −1.48% to −0.33%). In terms of body weight, treatment with saxagliptin was associated with no significant decreases in Chinese type 2 diabetes mellitus (T2DM) patients (WMD, −0.17 kg, 95% CI, −4.26 to 3.92 kg). Treatment with sitagliptin and linagliptin was also associated with no significant changes in body weight (WMD, 0.16 and 0.11 kg, respectively, P > 0.05).
Conclusions:
In Chinese type 2 diabetes patients, the efficacy of glucose control in all five kinds of DPP-4 inhibitor treatments was well confirmed, and no significant change in body weight was found.
Get full access to this article
View all access options for this article.
References
1.
CaiX, HanX, LuoY, JiL: Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: a meta-analysis. J Diabetes, 2015; 7:347–359.
2.
KimYG, HahnS, OhTJ, et al.: Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia, 2013; 56:696–708.
3.
AmoriRE, LauJ, PittasAG: Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA, 2007; 298:194–206.
4.
FakhouryWK, LereunC, WrightD: A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology, 2010; 86:44–57.
5.
LiberatiA, AltmanDG, TetzlaffJ, et al.: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 2009; 6:e1000100.
6.
GuW, LiangL, WangS, et al.: Efficacy and safety of saxagliptin monotherapy or added to metformin in Chinese patients with type 2 diabetes mellitus: results from the 24-week, post-marketing SUNSHINE study. J Diabetes, 2016; 8:809–815.
7.
YangS, GuY, LiZ, et al.: Effect of saxagliptin or glimepiride combined with glargine on blood glucose fluctuations in type 2 diabetic patients. Chin J Diabetes, 2015; 23:237–240.
8.
WangM, LinS, ChenY, et al.: Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin. Diab Res Clin Pract, 2015; 108:e67–e70.
9.
ZhuF, SongX: Therapeutic effects of dipeptidyl peptidase-4 inhibitor saxagliptin on patients with type w diabetes and its influences on β-cell function. Chin J Diabetes, 2014; 6:494–496.
10.
Li CJ, YuQ, YuP, et al.: Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes. Exp Clin Endocrinol Diabetes, 2014; 122:469–476.
11.
LvC, YuP, ZhouS, et al.: Eficacy and safety of saxagliptin combined metformin in newly diagnosed type 2 diabetes mellitus patients. Chin J Diabetes Mellitus, 2013; 5:759–762.
12.
PanCY, YangW, TouC, et al.: Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev, 2012; 28:268–275.
13.
YangW, PanCY, TouC, et al.: Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes research and clinical practice, 2011; 94:217–224.
14.
LiCJ, LiuXJ, BaiL, et al.: Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol Metab Syndr, 2014; 6:69–77.
15.
DuJ, LiangL, FangH, et al.: Efficacy and Safety of Saxagliptin Add-On to Metformin Compared with Acarbose Add-On to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin Monotherapy. American Diabetes Association 76th Scientific Sessions. Poster Presentation 1122-P.
16.
YuX, ZhaoQ: Sitagliptin as add-on to glargine insulin versus repaglinide as add-on to glargine in the treatment of T2DM-A report of clinical observation. Chin J Diabetes, 2013; 21:336–338.
17.
JinQ, ChenH, KongJ: The efficacy of DPP-4 inhibitor sitagliptin on type 2 diabetes patients. Chin Gerontol J, 2013; 33:4105–4106.
18.
LiW, LinM, ZhangX: Comparison on adding sitagliptin or glimepiride in poorly controlled overweight type 2 diabetes with oral metformin. Chin Hosp Pharm J, 2012; 32:792–794.
19.
YangW, GuanY, ShentuY, et al.: The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes, 2012; 4:227–237.
20.
MohanV, YangW, SonHY, et al.: Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract, 2009; 83:106–116.
21.
TangYZ, WangG, JiangZH, et al.: Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent. Diabetol Metab Syndr, 2015; 7:91–99.
22.
JiL, HanP, WangX, et al.: A Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to chinese patients with type 2 diabetes mellitus. J Diab Invest, 2016; 7:727–736.
23.
PanC, JiQ, YangW, et al.: Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week multi-center, double-blind, double-dummy, active-controlled, randomized trial. Chin J Endocrinol Metab, 2009:386–390.
24.
PanC, XingX, HanP, et al.: Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab, 2012; 14:737–744.
25.
XuL, LinK, DengH, et al.: Therapeutic effect of vildagliptin and insulin aspart injection in elderly patients with type 2 diabetes. J South Med Univ, 2014; 34:1515–1518.
26.
SuY, LvL, LiQ, et al.: A randomized controlled clinical trials for the treatment of type 2 diabetes by vildagliptin and alpha-glucosidase inhibitor. Chin J New Drugs, 2014; 23:2655–2658.
27.
YangW, XingX, LvX, et al.: Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus. J Diabetes, 2015; 7:174–181.
28.
NingG, WangW, LiL, et al.: Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. J Diabetes, 2016; 8:345–353.
29.
JiLN, PanCY, LuJM, et al.; for the VISION Study Group. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy (VISION): a randomized, openlLabel, prospective study. Diabetes Obes Metab, 2016; 18:775–782.
30.
ChenX, WangJ, HuangX, et al.: Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea. Curr Med Res Opin, 2016; 32:1131–1136.
31.
JiL, ZinmanB, PatelS, et al.: Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-Naïve patients with type 2 diabetes: a double-blind randomized trial. Adv Ther, 2015; 32:201–215.
32.
ZengZ, YangJK, TongN, et al.: Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial. Curr Med Res Opin, 2013; 29:921–929.
33.
WangW, YangJ, YangG, et al.: Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: a multinational 24-week, randomized clinical trial. J Diabetes, 2016; 8:229–237.
34.
WuW, LiY, ChenX, et al.: Effect of linagliptin on glycemic control in chinese patients with newly-diagnosed, drug-naïve type 2 diabetes mellitus: a randomized controlled trial. Med Sci Monit, 2015; 21:2678–2684.
35.
PanC, LiW, ZengJ, et al.: Efficacy and safety of alogliptin in treatment of type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial in mainland China. Chin J Intern Med, 2015; 54:949–953.
36.
SchweizerA, CouturierA, FoleyJE, DejagerS: Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med, 2007; 24:955–961.
37.
DeaconCF: Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab, 2011; 13:7–18.
38.
TatosianDA, GuoY, SchaefferAK, et al.: Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. Diabetes Ther, 2013; 4:431–442.
39.
EspositoK, ChiodiniP, CapuanoA, et al.: Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors. Endocrine, 2014; 46:43–51.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
